Local public health response to vaccine-associated measles: case report

Simple item page
dc.contributor.authorHau, Monica
dc.contributor.authorSchwartz, Kevin L
dc.contributor.authorFrenette, Crystal
dc.contributor.authorMogck, Isabelle
dc.contributor.authorGubbay, Jonathan B
dc.contributor.authorSeverini, Alberto
dc.contributor.authorHiebert, Joanne
dc.contributor.authorDeeks, Shelley L
dc.contributor.authorMorris, Shaun K
dc.date.accessioned2013-04-11T11:03:02Z
dc.date.available2013-04-11T11:03:02Z
dc.date.issued2013-03-25
dc.date.updated2013-04-11T11:03:02Z
dc.description.abstractAbstract Background The most appropriate public health approach to vaccine-associated measles in immunocompromised patients is unknown, mainly because these cases are rare and transmission of vaccine-associated measles has not been previously documented. In this case report, we describe Peel Public Health’s response to a vaccine-associated measles case in an immunocompromised child in Ontario, Canada. Case presentation A five-year-old Canadian-born boy with a history of a hematopoetic stem cell transplant three years previously received live attenuated measles, mumps, and rubella (MMR) vaccine. Over the subsequent 7 to 14 days, he developed an illness clinically consistent with measles. There was no travel history or other measles exposure. Serology and polymerase chain reaction (PCR) testing confirmed acute measles infection. Following discussion with pediatric infectious diseases specialists, but prior to the availability of virus sequencing, it was felt that this case was most likely due to vaccine strain. Although no microbiologically confirmed secondary cases of vaccine-associated measles have been previously described, we sent notification letters to advise all contacts of measles symptoms since the likelihood of transmission from an immunocompromised patient was low, but theoretically possible. We decided to stratify contacts into immune competent and compromised and to deal with the latter group conservatively by excluding them as if they were exposed to wild-type measles because the risk of transmission of disease in this population, while presumably very low, is unknown. However, no contacts self-identified as immunocompromised and there were no secondary cases. Subsequent genotyping confirmed that this case was caused by vaccine strain measles virus. Conclusion The public health approach to contact tracing and exclusions for vaccine-associated measles in immunocompromised patients is unclear. The rarity of secondary cases provides further evidence that the risk to the general public is likely extremely low. Although the risk appears negligible, exclusion and administration of immune globulin may be considered for susceptible, immunocompromised contacts of cases of vaccine-associated measles in immunocompromised patients.
dc.description.versionPeer Reviewed
dc.identifier.citationBMC Public Health. 2013 Mar 25;13(1):269
dc.identifier.doihttp://dx.doi.org/10.1186/1471-2458-13-269
dc.identifier.urihttp://hdl.handle.net/1993/18727
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderMonica Hau et al.; licensee BioMed Central Ltd.
dc.titleLocal public health response to vaccine-associated measles: case report
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
1471-2458-13-269.xml
Size:
28.92 KB
Format:
Extensible Markup Language
Description:
Download
Thumbnail Image
Name:
1471-2458-13-269.pdf
Size:
144.58 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works